Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABX203 + nucleos(t)ide analogs
- Development stage
- Discontinued
- Lead developer
- Abivax
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intranasal, Subcutaneous, Oral
01
Overview
ABX203 (also known as Nasvac) is a therapeutic vaccine developed for the treatment of chronic hepatitis B (CHB). It consists of a 1:1 combination of two recombinant proteins: the Hepatitis B surface antigen (HBsAg) and the Hepatitis B core antigen (HBcAg). The vaccine is designed to break immune tolerance in CHB patients by stimulating both systemic and mucosal immune responses, particularly cytotoxic T-lymphocyte (CTL) activity. In clinical development, ABX203 was evaluated in combination with standard-of-care nucleos(t)ide analogs (NAs), which are oral antivirals that inhibit HBV DNA polymerase. The goal of this combination therapy was to achieve a functional cure, characterized by sustained HBsAg loss and undetectable HBV DNA after the cessation of NA therapy. While Abivax discontinued its development program in 2016 after a Phase 2b trial failed to meet its primary endpoint, the vaccine continues to be produced and used in certain regions under the name Nasvac.
- Brand names
- Nasvac
- Other names
- HBsAg/HBcAg vaccineNASVAC
02
Targets
HBV Pol (Hepatitis B virus polymerase)HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on ABX203 + nucleos(t)ide analogs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABX203 + nucleos(t)ide analogs.